Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Reporting - Significant expense categories (Details)

v3.25.1
Segment Reporting - Significant expense categories (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Operating expenses:    
Net Operating Loss: $ (16,827,478) $ (14,262,733)
Net (Income) Loss: $ (2,778,873) $ 13,212,482
Other segment items description Other segment items included in segment (income) loss include changes in warrant liability, interest income, and interest expense, and in 2024 Loss on issuance of common shares, warrants, and pre-funded warrants in July 2024 PIPE Other segment items included in segment (income) loss include changes in warrant liability, interest income, and interest expense, and in 2024 Loss on issuance of common shares, warrants, and pre-funded warrants in July 2024 PIPE
Life science | Operating segment    
Operating expenses:    
PMN310 development program costs $ 8,275,268 $ 4,776,411
Other non-employee research and development costs 772,501 1,602,164
Employee costs 3,336,580 3,102,238
Other general and administrative costs 4,443,129 4,781,920
Net Operating Loss: 16,827,478 14,262,733
Other segment items (19,606,351) (1,050,251)
Net (Income) Loss: $ (2,778,873) $ 13,212,482